184AA3: a xenograft model of ER+ breast adenocarcinoma

William C. Hines, Irene Kuhn, Kate Thi, Berbie Chu, Gaelen Stanford-Moore, Rocío Sampayo, James C. Garbe, Martha Stampfer, Alexander D Borowsky, Mina J. Bissell

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Despite the prevalence and significant morbidity resulting from estrogen receptor positive (ER+) breast adenocarcinomas, there are only a few models of this cancer subtype available for drug development and arguably none for studying etiology. Those models that do exist have questionable clinical relevance. Given our goal of developing luminal models, we focused on six cell lines derived by minimal mutagenesis from normal human breast cells, and asked if any could generate clinically relevant xenografts, which we then extensively characterized. Xenografts of one cell line, 184AA3, consistently formed ER+ adenocarcinomas that had a high proliferative rate and other features consistent with “luminal B” intrinsic subtype. Squamous and spindle cell/mesenchymal differentiation was absent, in stark contrast to other cell lines that we examined or others have reported. We explored intratumoral heterogeneity produced by 184AA3 by immunophenotyping xenograft tumors and cultured cells, and characterized marker expression by immunofluorescence and flow cytometry. A CD44High subpopulation was discovered, yet their tumor forming ability was far less than CD44Low cells. Single cell cloning revealed the phenotypic plasticity of 184AA3, consistent with the intratumoral heterogeneity observed in xenografts. Characterization of ER expression in cultures revealed ER protein and signaling is intact, yet when estrogen was depleted in culture, and in vivo, it did not impact cell or tumor growth, analogous to therapeutically resistant ER+ cancers. This model is appropriate for studies of the etiology of ovarian hormone independent adenocarcinomas, for identification of therapeutic targets, predictive testing, and drug development.

Original languageEnglish (US)
Pages (from-to)37-52
Number of pages16
JournalBreast Cancer Research and Treatment
Volume155
Issue number1
DOIs
StatePublished - Jan 1 2016

Fingerprint

Heterografts
Adenocarcinoma
Breast
Cell Line
Neoplasms
Cultured Tumor Cells
Immunophenotyping
Mutagenesis
Estrogen Receptors
Pharmaceutical Preparations
Fluorescent Antibody Technique
Organism Cloning
Cell Differentiation
Flow Cytometry
Estrogens
Epithelial Cells
Hormones
Morbidity
Growth
Proteins

Keywords

  • Intratumoral heterogeneity
  • Luminal breast cancer models
  • Microenvironment
  • Xenograft

ASJC Scopus subject areas

  • Medicine(all)
  • Oncology
  • Cancer Research

Cite this

Hines, W. C., Kuhn, I., Thi, K., Chu, B., Stanford-Moore, G., Sampayo, R., ... Bissell, M. J. (2016). 184AA3: a xenograft model of ER+ breast adenocarcinoma. Breast Cancer Research and Treatment, 155(1), 37-52. https://doi.org/10.1007/s10549-015-3649-z

184AA3 : a xenograft model of ER+ breast adenocarcinoma. / Hines, William C.; Kuhn, Irene; Thi, Kate; Chu, Berbie; Stanford-Moore, Gaelen; Sampayo, Rocío; Garbe, James C.; Stampfer, Martha; Borowsky, Alexander D; Bissell, Mina J.

In: Breast Cancer Research and Treatment, Vol. 155, No. 1, 01.01.2016, p. 37-52.

Research output: Contribution to journalArticle

Hines, WC, Kuhn, I, Thi, K, Chu, B, Stanford-Moore, G, Sampayo, R, Garbe, JC, Stampfer, M, Borowsky, AD & Bissell, MJ 2016, '184AA3: a xenograft model of ER+ breast adenocarcinoma', Breast Cancer Research and Treatment, vol. 155, no. 1, pp. 37-52. https://doi.org/10.1007/s10549-015-3649-z
Hines WC, Kuhn I, Thi K, Chu B, Stanford-Moore G, Sampayo R et al. 184AA3: a xenograft model of ER+ breast adenocarcinoma. Breast Cancer Research and Treatment. 2016 Jan 1;155(1):37-52. https://doi.org/10.1007/s10549-015-3649-z
Hines, William C. ; Kuhn, Irene ; Thi, Kate ; Chu, Berbie ; Stanford-Moore, Gaelen ; Sampayo, Rocío ; Garbe, James C. ; Stampfer, Martha ; Borowsky, Alexander D ; Bissell, Mina J. / 184AA3 : a xenograft model of ER+ breast adenocarcinoma. In: Breast Cancer Research and Treatment. 2016 ; Vol. 155, No. 1. pp. 37-52.
@article{c6a87ecd509b4913953a2ccd28b31b06,
title = "184AA3: a xenograft model of ER+ breast adenocarcinoma",
abstract = "Despite the prevalence and significant morbidity resulting from estrogen receptor positive (ER+) breast adenocarcinomas, there are only a few models of this cancer subtype available for drug development and arguably none for studying etiology. Those models that do exist have questionable clinical relevance. Given our goal of developing luminal models, we focused on six cell lines derived by minimal mutagenesis from normal human breast cells, and asked if any could generate clinically relevant xenografts, which we then extensively characterized. Xenografts of one cell line, 184AA3, consistently formed ER+ adenocarcinomas that had a high proliferative rate and other features consistent with “luminal B” intrinsic subtype. Squamous and spindle cell/mesenchymal differentiation was absent, in stark contrast to other cell lines that we examined or others have reported. We explored intratumoral heterogeneity produced by 184AA3 by immunophenotyping xenograft tumors and cultured cells, and characterized marker expression by immunofluorescence and flow cytometry. A CD44High subpopulation was discovered, yet their tumor forming ability was far less than CD44Low cells. Single cell cloning revealed the phenotypic plasticity of 184AA3, consistent with the intratumoral heterogeneity observed in xenografts. Characterization of ER expression in cultures revealed ER protein and signaling is intact, yet when estrogen was depleted in culture, and in vivo, it did not impact cell or tumor growth, analogous to therapeutically resistant ER+ cancers. This model is appropriate for studies of the etiology of ovarian hormone independent adenocarcinomas, for identification of therapeutic targets, predictive testing, and drug development.",
keywords = "Intratumoral heterogeneity, Luminal breast cancer models, Microenvironment, Xenograft",
author = "Hines, {William C.} and Irene Kuhn and Kate Thi and Berbie Chu and Gaelen Stanford-Moore and Roc{\'i}o Sampayo and Garbe, {James C.} and Martha Stampfer and Borowsky, {Alexander D} and Bissell, {Mina J.}",
year = "2016",
month = "1",
day = "1",
doi = "10.1007/s10549-015-3649-z",
language = "English (US)",
volume = "155",
pages = "37--52",
journal = "Breast Cancer Research and Treatment",
issn = "0167-6806",
publisher = "Springer New York",
number = "1",

}

TY - JOUR

T1 - 184AA3

T2 - a xenograft model of ER+ breast adenocarcinoma

AU - Hines, William C.

AU - Kuhn, Irene

AU - Thi, Kate

AU - Chu, Berbie

AU - Stanford-Moore, Gaelen

AU - Sampayo, Rocío

AU - Garbe, James C.

AU - Stampfer, Martha

AU - Borowsky, Alexander D

AU - Bissell, Mina J.

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Despite the prevalence and significant morbidity resulting from estrogen receptor positive (ER+) breast adenocarcinomas, there are only a few models of this cancer subtype available for drug development and arguably none for studying etiology. Those models that do exist have questionable clinical relevance. Given our goal of developing luminal models, we focused on six cell lines derived by minimal mutagenesis from normal human breast cells, and asked if any could generate clinically relevant xenografts, which we then extensively characterized. Xenografts of one cell line, 184AA3, consistently formed ER+ adenocarcinomas that had a high proliferative rate and other features consistent with “luminal B” intrinsic subtype. Squamous and spindle cell/mesenchymal differentiation was absent, in stark contrast to other cell lines that we examined or others have reported. We explored intratumoral heterogeneity produced by 184AA3 by immunophenotyping xenograft tumors and cultured cells, and characterized marker expression by immunofluorescence and flow cytometry. A CD44High subpopulation was discovered, yet their tumor forming ability was far less than CD44Low cells. Single cell cloning revealed the phenotypic plasticity of 184AA3, consistent with the intratumoral heterogeneity observed in xenografts. Characterization of ER expression in cultures revealed ER protein and signaling is intact, yet when estrogen was depleted in culture, and in vivo, it did not impact cell or tumor growth, analogous to therapeutically resistant ER+ cancers. This model is appropriate for studies of the etiology of ovarian hormone independent adenocarcinomas, for identification of therapeutic targets, predictive testing, and drug development.

AB - Despite the prevalence and significant morbidity resulting from estrogen receptor positive (ER+) breast adenocarcinomas, there are only a few models of this cancer subtype available for drug development and arguably none for studying etiology. Those models that do exist have questionable clinical relevance. Given our goal of developing luminal models, we focused on six cell lines derived by minimal mutagenesis from normal human breast cells, and asked if any could generate clinically relevant xenografts, which we then extensively characterized. Xenografts of one cell line, 184AA3, consistently formed ER+ adenocarcinomas that had a high proliferative rate and other features consistent with “luminal B” intrinsic subtype. Squamous and spindle cell/mesenchymal differentiation was absent, in stark contrast to other cell lines that we examined or others have reported. We explored intratumoral heterogeneity produced by 184AA3 by immunophenotyping xenograft tumors and cultured cells, and characterized marker expression by immunofluorescence and flow cytometry. A CD44High subpopulation was discovered, yet their tumor forming ability was far less than CD44Low cells. Single cell cloning revealed the phenotypic plasticity of 184AA3, consistent with the intratumoral heterogeneity observed in xenografts. Characterization of ER expression in cultures revealed ER protein and signaling is intact, yet when estrogen was depleted in culture, and in vivo, it did not impact cell or tumor growth, analogous to therapeutically resistant ER+ cancers. This model is appropriate for studies of the etiology of ovarian hormone independent adenocarcinomas, for identification of therapeutic targets, predictive testing, and drug development.

KW - Intratumoral heterogeneity

KW - Luminal breast cancer models

KW - Microenvironment

KW - Xenograft

UR - http://www.scopus.com/inward/record.url?scp=84953363815&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84953363815&partnerID=8YFLogxK

U2 - 10.1007/s10549-015-3649-z

DO - 10.1007/s10549-015-3649-z

M3 - Article

C2 - 26661596

AN - SCOPUS:84953363815

VL - 155

SP - 37

EP - 52

JO - Breast Cancer Research and Treatment

JF - Breast Cancer Research and Treatment

SN - 0167-6806

IS - 1

ER -